ABSTRACT
Background The novel coronavirus SARS-CoV-2 (COVID-19) emerged in December 2019 in Wuhan, China and has spread since then to around 210 countries and territories by April 2020. Consequently, countries have adopted physical distance measures in an attempt to mitigate the uncontrolled spread of the virus. A critical question for policymakers to inform evidence-based practice is if and how physical distance measures slowed the propagation of COVID-19 in the early phase of the pandemic.
Methods This study aims to quantify the effects of physical distance mitigation measures on the propagation of the COVID-19 pandemic. Data from John Hopkins University on confirmed cases and testing data from the Our World in Data were used in an interrupted time series analysis to estimate the effects of physical distance measures on the growth rates of the pandemic in 12 countries of Asia, Africa, and Europe.
Findings We found that physical distance measures produced a significant decrease in the growth rates of the COVID-19 pandemic in five countries (Austria, Belgium, Italy, Malaysia, and South Korea). The test-positivity rate was significant in understanding the slowing growth rate of COVID-19 cases caused by the mitigation measures, as it provides important context that is missing from analysis based only on confirmed case data.
Interpretation Physical distance interventions effectively slowed the progression of the COVID-19 pandemic. The results of this study could inform infectious disease mitigation policies based on physical distance measures by quantifying the differential health outcomes of a pandemic with and without physical distance interventions.
Evidence before this study The SARS-CoV-2 is a new virus identified in December 2019 in the province of Wuhan, China and as never before, a remarkable number of studies and reports have been released since the start of the pandemic. Several studies have used confirmed COVID-19 cases to estimate the growth rate of the pandemic. However, many studies have discussed limitations of including only confirmed cases attributable to the lack of information about testing protocols and testing rates among different countries. Finally, some researchers proposed the analysis of reported deaths by COVID-19 as a potential solution. However, this metric results in biased estimates because deaths by COVID-19 are known to be underreported.
Added value of this study We designed and implemented analytic methods based on our previous research applied to different infectious disease epidemics, to add evidence related to the impact of non-pharmaceutical containment strategies on the temporal progression of the COVID-19 pandemic. Specifically, this study adds quantitative evidence about the effects of physical distance measures on limiting the propagation of COVID-19 pandemics in different countries. Additionally, we included testing data in the analysis to assess intra- and inter-country variation in testing growth rates. We hypothesized that the test-positivity rate is an approximation to the incidence of the COVID-19 pandemics in countries with high testing rates. Additionally, we hypothesize that a significant decrease in the pandemic over time could be identified by a significant decrease in the confirmed cases along with a significant decrease in the test-positivity rate. Our results quantified the potential effects of physical distance interventions on the COVID-19 pandemic progression under different levels of testing and enforcement of mitigation policies.
Implications of all the available evidence Our analysis could lead to better approaches for estimating the effects of physical distance measures on the time course of infectious diseases. In addition, our analysis highlights the potential bias of estimated COVID-19 growth rates based only on confirmed cases. The results from our study could inform strategies for mitigating the COVID-19 or other future pandemics, especially in countries in an earlier stage of a pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There is no funding to declare
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are openly available in the Johns Hopkins University Center for Systems Science and Engineering (https://github.com/CSSEGISandData/COVID-19)
